David O’Connell, director of scientific affairs at PCI Pharma Services, explores how enabling technologies are helping targeted protein degraders (TPDs) overcome their biggest challenge.
European Pharmaceutical Manufacturer speaks to Carole Grassi, chief commercial marketing & innovation officer, SGD Pharma about what the company is showcasing at CPHI Frankfurt.
During a recent visit to ReiThera's facilities, I saw first-hand how the company is leveraging decades of vector expertise, manufacturing capabilities, and a focus on quality to help clients bring gene therapies and vaccines from concept to clinic.
On 10th November at 9:00 AM - 9:30 AM CT, Sarang Oka, scientific fellow, Hovione, will do a talk titled "Addressing Practical Challenges in CM via Novel Hardware and Automation" at PharmSci360 in San Antonio, TX.
Boyds’ chief development officer, Dr Nick Meyers, and director of regulatory affairs, Dr Eric Hardter, provide advice and guidance to drug developers and sponsors on de-risking the Investigational New Drug (IND) process.
